核苷酸切除修复交叉互补组1在晚期乳腺癌中的表达及其与顺铂耐药性的临床研究  

ERCC1 expression in advanced breast cancer and its relationship with cisplatin resistance

作　　者：鲁凯[1] 刘燕文[2] 李惠[4] 刘东[1] 叶红玲[3] 徐良[1] 刘苏[1] 

机构地区：[1]连云港市第二人民医院甲乳外科,222023 [2]连云港市第二人民医院肿瘤科,222023 [3]连云港市第二人民医院检验科,222023 [4]江苏省中医院检验科,210029

出　　处：《中华内分泌外科杂志》2016年第2期139-143,共5页Chinese Journal of Endocrine Surgery

基　　金：连云港市科技局社会发展计划（SH1333）

摘　　要：目的研究核苷酸切除修复交叉互补组1（excision repair cross comple mentinggene1，ERCC1）在晚期乳腺癌中的表达及其与顺铂耐药性的关系。方法应用实时定量荧光PCR（RT-QPCR）技术检测50例晚期乳腺癌组织中ERCC1的表达，CAF方案对其行辅助化疗，后因出现不同程度肺／肝／淋巴结转移，接受吉西他滨＋顺铂的方案进行化疗，研究ERCC1与顺铂耐药性的关系。结果ERCC1基因表达与年龄，淋巴结转移，临床分期无明显相关性．与组织学分级及HER2的表达亦无明显相关性，化疗有效组中，ERCC1高表达者的比例为18．8％（3／16），低表达的比例为79．4％（27／34），ERCC1低表达的乳腺癌患者对顺铂敏感性高，高表达者对顺铂敏感性低，2者的有效率（（完全缓解（completeremission，CR）＋部分缓解（partialremis—sion，PR））及无效率（（疾病稳定（stabledisease，SD）＋疾病进展（progressivedisease，PD））差异有统计学意义（P〈0．001）。结论ERCC1低表达的晚期乳腺癌患者可从顺铂类药物获益，ERCC1可作为乳腺癌化疗的分子预测指标。Objective To investigate ERCC1 expression in advanced breast cancer and its relationship with cisplatin resistance. Methods ERCC1 expression in 50 cases of advanced breast cancer was measured by RT-QPCR. The chemotherapy （CAF） was given. Gemcitabine and cisplatin were given because of metastasis. Results The expression of ERCC 1 has no relationship with age, lymph node metastasis, clinic1 stage, histological grade or human epidermal growth factor receptor-2 （HER2） expression. The effective rate was 18.8% （3/16） for ERCC1 high-expressed patients and 79.4% （27/34）for ERCC1 low-expressed patients in terms of cisplatin chemotherapy. The sensitity for cisplatin chemotherapy was high for patients with low ERCC1 expression and it was low for patients with high ERCC1 expression. The effective rate （complete remission＋partial remission）, and ineffective rate （stable disease＋progressive disease） between the two had statastical significance （P〈0.001）. Conclusions ERCC1 low-expressed patients can benefit from cisplatin. ERCC1 can be used as a moleculer marker for predicting chemotherapy efficacy in breast cancer.

关 键 词：乳腺癌 ERCC1基因 实时定量荧光核酸扩增检测 顺铂 

分 类 号：R737.9[医药卫生—肿瘤]